Monoclonal Antibodies Against Claudin-18 for Treatment of Cancer
AssigneesGanymed Pharmaceuticals AG, Johannes Gutenberg-Universitat
InventorsUgur Sahin, Ozlem Tureci, Gunda Brandenburg, Dirk Usener
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof.
Claims35
An antibody having the ability of binding to CLD18 and mediating killing or inhibition of proliferation of cells expressing CLD18.
An antibody produced by a clone deposited under the accession no. DSM ACC2737, DSM ACC2738, DSM ACC2739, DSM ACC2740, DSM ACC2741, DSM ACC2742, DSM ACC2743, DSM ACC2745, DSM ACC2746, DSM ACC2747, DSM ACC2748, DSM ACC2808, DSM ACC2809, or DSM ACC2810.
A hybridoma deposited under the accession no. DSM ACC2737, DSM ACC2738, DSM ACC2739, DSM ACC2740, DSM ACC2741, DSM ACC2742, DSM ACC2743, DSM ACC2745, DSM ACC2746, DSM ACC2747, DSM ACC2748, DSM ACC2808, DSM ACC2809, or DSM ACC2810.
29-30. (canceled)
Dependencies are inferred from the claim text.